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Background: Machado-Joseph disease (MJD), also named spinocerebellar ataxia type 3 (SCA3) is the most common
autosomal dominant ataxia worldwide. Although nystagmus is one of the most frequently reported ocular alterations
in MJD patients its behaviour during the course of the disease, namely in its early stages, has only recently started to
be investigated. The main goal of this work was to characterize the frequency of nystagmus in symptomatic and
presymptomatic carriers of the MJD mutation, and investigate its usefulness as an early indicator of the disease.
Methods: We conducted an observational study of Azorean MJD family members, comprising a total of 158 subjects
which underwent neurological evaluation. Sixty eight were clinically and molecularly diagnosed with MJD, 48 were
confirmed asymptomatic carriers and 42 were confirmed non-carriers of the MJD mutation. The frequency of nystagmus
was calculated for the 3 groups.
Results: Nystagmus was present in 88% of the MJD patients. Seventeen percent of the at-risk subjects with a carrier
result in the molecular test and none of the 42 individuals who received a non-carrier test result displayed nystagmus
(p < 0.006). Although not reaching statistical significance, symptomatic subjects showing nystagmus had a tendency for
a higher length of the CAG tract in the expanded allele, when compared to individuals who did not have nystagmus.
Conclusions: The frequency of nystagmus in asymptomatic carriers and its absence in non-carriers of the mutation,
suggests that nystagmus may appear before gait disturbance and can thus be considered an early sign of MJD.
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Machado-Joseph disease (MJD; MIM #109150; ORPHA
98757), also known as spinocerebellar ataxia type 3
(SCA3), is the most frequent autosomal dominant ataxia
worldwide [1]. The MJD gene (ATXN3) was mapped to
14q32.1 and the causative mutation was identified as a
coding unstable CAG expansion [2,3]; normal alleles
consensually range from 12 to 44 CAGs, whereas well
established limits for expanded alleles comprise from 61
to 87 repeats [4].
With an average onset in adulthood (around 40 years),
MJD is characterized by a wide range of clinical manifesta-
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stated.pyramidal and extrapyramidal signs, dystonia with rigidity
and distal muscular atrophies [5,6]. Gait ataxia is reported
as the initial complaint in the majority of MJD patients [7];
in some of the cases, other symptoms, such as diplopia
have been reported as preceding gait instability [8]. Ocular
alterations are clinical features commonly described in
SCAs, occurring as a consequence of cerebellar and
brainstem degeneration [9]. Amongst such alterations is
nystagmus, a clinical sign associated with vestibular nu-
clei, found to be damaged in MJD post-mortem brains
[10]. Nystagmus is one of the most frequently reported
ocular alterations in MJD patients [7,11,12]; its behav-
iour during the course of the disease, namely in its early
stages, has only recently started to be investigated [13].
The main goal of this work was to characterize the fre-
quency of nystagmus in symptomatic and presymptomatic
carriers of the MJD mutation and investigate its usefulness
as an early indicator of the disease. The availability ofLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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MJD mutation, associated with biological and/or refined
clinical markers of the disease process, would enable an
early intervention with prophylactic treatment, which
should lead to prevention, or at least delayed onset or
slowed progression, by allowing intervention before the
appearance of motor symptoms [14].
Methods
Subjects
From 1996 to 2011, 158 subjects belonging to 21 Azorean
MJD families performed the molecular test for MJD, either
in the context of molecular diagnosis (N = 68) or predict-
ive testing (PT) (N = 90). Subjects were asked for written
informed consent to participate in research concerning
the analysis of the clinical variability of MJD. During this
period the molecular tests have been conducted by two
distinct Portuguese genetic diagnosis laboratories.
Three main groups were defined for this study:
Group 1- subjects with a clinical and molecular diagno-
sis of MJD (N= 68). This group corresponds to individuals
that were already symptomatic at the time of their first
observation, and for which a molecular confirmation of
MJD was subsequently obtained; Group 2- subjects with
a normal neurological evaluation, who were confirmed
as carriers of the ATXN3 mutation in the molecular test
(N = 48). Group 2 was therefore formed by subjects that
were submitted to a neurological examination upon en-
tering the PT program (before taking the molecular
test) and were asymptomatic at that time. Some of the
subjects from this group developed motor symptoms
during the observational period of the study. For genotype-
phenotype analysis these subjects were clustered with pa-
tients from group 1, constituting the pool of “symptomatic
subjects” (N = 87).
Group 3- subjects with a normal pre-test clinical evalu-
ation and that subsequently received a negative result in
the molecular test (non-carriers of the ATXN3 mutation)
(N = 42).
This study is part of a larger project which was approved
by the Ethics Committee of the Hospital do Divíno Espírito
Santo (São Miguel Island, Azores – Portugal).
Clinical features
Neurological examination was performed by two experi-
enced neurologists, following the protocol established by
Coutinho [7]. The examination included the evaluation of
nystagmus, which consists in small, horizontal, saccade-
like movements that lead the eye away from the target tra-
jectory and, after a delay, bring it back onto the target
[9,15]. The evaluation of nystagmus followed the ICARS
procedure [16]. The age at onset and the duration of
disease were also assessed. Onset corresponded to the
age of appearance of the first symptoms (such as gaitdisturbance) reported by the patient and/or a close rela-
tive. Disease duration was calculated as the time elapsed
between the age at onset and the last neurological
evaluation available. Time from onset was calculated as
the difference between age at first neurological observa-
tion and reported age at onset of ataxia.
Statistical analysis
Differences in the frequency of nystagmus among the
three study groups were measured by the Fisher’s Exact
Test. Unrelated subjects (N = 46) from the pool of symp-
tomatic subjects were analysed for the following vari-
ables: CAG length of the normal and expanded allele,
age at onset and disease duration. Pearson correlation
test was performed to evaluate the relationship between
the CAG repeat length of normal and expanded alleles
and age at onset. Univariate and multivariate linear regres-
sion were used to test the effect of several predictors on
age at onset, namely: the number of CAGs in expanded
and normal alleles, gender, island of origin, molecular
diagnosis laboratory, and presence/absence of nystagmus.
The best model was used to predict the age at onset for all
members of group 2. The results were accepted as statisti-
cally significant whenever p < 0.05. All analyses were per-
formed with PASW Statistics 18 [17].
Results
Frequency of nystagmus in symptomatic and
presymptomatic MJD carriers
For the 158 Azorean subjects included in the study, in-
formation on gender, age and size of the CAG tract of
MJD alleles is displayed in Table 1. Mean age is higher
in group 1 (48 ± 15 years), than in the other 2 studied
groups (30 ± 9 and 36 ± 12, respectively). The number of
CAG repeats in the expanded allele is 71 ± 4 (mean ±
Standard Deviation - SD) in both group 1 and group 2
(Table 1). Nystagmus was present in 88% of the MJD pa-
tients (group 1) and 17% of the at-risk subjects with a
carrier result in the molecular test (group 2). However,
nystagmus was not observed in any of the 42 individuals
who received a non-carrier test result (group 3), which
resulted in significant differences between groups 2 and
3 (p = 0.006).
From the 68 patients in group 1, only eight (12%)
failed to present nystagmus at the first neurological
examination; five out of these eight, however, presented
nystagmus at the last observation performed in the
course of this study, increasing to 96% the number of
patients who presented nystagmus. The remaining three
patients were lost from follow-up, therefore preventing
the verification of the presence of nystagmus at a later
stage of the disease.
From the group of 48 asymptomatic carriers (group 2),
19 (40%) developed gait disturbance within the period of
Table 1 Characterization of the studied subjects according to group assignment
N Group 1 N Group 2 N Group 3
Gender 68 33♀|35♂ 48 29♀|19♂ 42 26♀|17♂
Age 68 48 ± 15 [16–82] 48 30 ± 9 [18–59] 42 36 ± 12 [18–60]
CAG repeats
Normal allele 60 20 ± 5 [13–28] 44 22 ± 5 [13–27] 42 17 ± 4 [13–27] 23 ± 4 [13–31]
Expanded allele 64 71 ± 4 [61–80] 46 71 ± 4 [63–80]
All variables were presented as mean ± standard deviation [range]. Gender was represented as ♀ for female and ♂ for male.
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at PT evaluation and developed gait ataxia during the
follow-up period; the remaining 3 were not re-evaluated
(Figure 1). Fourteen individuals from group 2 also devel-
oped gait ataxia during this period (Figure 1); for such
subjects nystagmus, although absent in the respective
PT evaluation, was present at the latest observation per-
formed. Individuals which presents nystagmus at PT
evaluation were closest to reported age at onset (median
of 2 years) than individuals without nystagmus (median
of 3 years).Genotype-phenotype correlations
The 87 symptomatic carriers were clinically characterized,
showing a mean value for age at onset of 39 ± 12 years
(mean ± standard deviation) and disease duration of 15 ±
9 years. All subjects displayed cerebellar signs; moreover,
65% presented mostly corticospinal dysfunction, followed
by mostly peripheral (26%) and extrapyramidal (6%) mani-
festations (Figure 2).
Using information on unrelated symptomatic subjects
with available CAG data, a negative correlation between
the size of the expanded allele and the age at onset was
observed (N = 42, r = −0.667, p < 0.0005). The explanation
of the age at onset variance provided by the CAG length
in expanded allele was 45% (t = −5.740, p < 0.0005). An
improvement of the model using additional predictors
(CAG repeat number in normal allele, gender, island of
origin and genotyping laboratory) raised the explanationFigure 1 Age at onset, predicted age at onset and age at first observatio
developed the disease, divided by presence (N=5) and absence of nystagof the age at onset to 48% (p < 0.0005). Individuals show-
ing nystagmus had a tendency for a higher CAG length in
expanded allele, when compared to individuals who did
not have nystagmus [71.54 ± 0.67 and 69.71 ± 0.97 (mean ±
standard error), respectively]; this tendency, however, failed
to reach significance. The presence/absence of nystagmus
did not improve significantly the prediction of the age at
onset when adding this variable to the number of CAG
repeats in the expanded allele as well as the other predic-
tors previously mentioned.Discussion
The present study confirmed nystagmus as a very frequent
sign in MJD patients (up to 96% of the MJD patients from
the studied series), which is in agreement with previous
studies where this sign has been reported with frequencies
that vary between 55 and 92% [7,8,18,19]. Considering the
genotype-phenotype results, a long term follow-up study
would be needed to understand if there is a correlation be-
tween CAG repeat length in expanded allele and the age
of appearance of nystagmus.
The present study further shows that nystagmus is also
observed in carriers of the MJD mutation, before the
manifestation of gait disturbance, indicating that it can
be an early sign of the disease, which should be monitored
in mutation carriers even before motor signs appear. Re-
cently a higher rate of horizontal gaze-evoked nystagmus
in MJD carriers than non-carriers (ten [39%] of 26 vs one
[5%] of 20; p = 0 · 013) has been described [13]. Fromn was displayed in individuals from group 2, which during this study
mus (N=14).
Figure 2 Neurological features of MJD patients, such as age at onset (N = 86), disease duration (N = 81) and symptomatology (N = 68).
Cerebellar dysfunction was observed in all patients and therefore they were distinguished also by dysfunction in other systems: mostly
corticospinal, mostly extrapyramidal or mostly peripheral signs.
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mentary use of one that includes the evaluation of nystag-
mus, such as ICARS [16] or NESSCA [20] is important, to
avoid the under-estimation of this clinical sign and the
failure to detect early alterations. In other SCAs, early de-
tection of impaired eye movements in presymptomatic in-
dividuals has been a matter of study. Slowing of horizontal
saccades was observed in SCA1, 2, 6 and 7 [19,21-24]
whereas a decrease in pursuit gain was found in SCA6
[25]. The present study is based in the qualitative analysis
of nystagmus, i.e., presence or absence of this clinical sign;
although reasonable information about oculomotor move-
ments might be obtained with such qualitative measure,
the use of semi-quantitative techniques such as oculo-
graphic evaluations, should improve the characterization of
nystagmus types as well as the study of other ocular fea-
tures, which might help to further understand the import-
ance of eye abnormalities in early stages of MJD.
Conclusion
The presence of nystagmus in asymptomatic MJD car-
riers suggests that the detection of this sign might be
useful in the identification of early stages of MJD, poten-
tially facilitating the enrolment of presymptomatic indi-
viduals in future preventive clinical trials.
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